- Home
- CLDX vs TARS Comparison
CLDX vs TARS Comparison
Compare CLDX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLDX | TARS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLDX | TARS |
|---|---|---|
| Price | $38.90 | $83.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $46.60 | ★ $89.00 |
| AVG Volume (30 Days) | 694.0K | ★ 745.3K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | N/A | ★ N/A |
| Revenue | $12,743,000.00 | ★ $451,360,000.00 |
| Revenue This Year | $111.39 | $56.43 |
| Revenue Next Year | $235.85 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 87.78 | ★ 146.71 |
| 52 Week Low | $22.10 | $48.20 |
| 52 Week High | $45.14 | $91.53 |
Technical Indicators
Market Signals| Indicator | CLDX | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 66.38 |
| Support Level | $28.51 | $60.95 |
| Resistance Level | $40.30 | $84.66 |
| Average True Range (ATR) | 1.37 | 3.63 |
| MACD | -0.36 | 1.23 |
| Stochastic Oscillator | 9.94 | 64.47 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.